Table 4 Immunotherapy trials addressing thyroid cancer
From: Novel targeted therapies and immunotherapy for advanced thyroid cancers
Immunological Target | Trial | Brief description |
|---|---|---|
TAM | NCT01346358 | CSF-1R antibody LY3022855 (also known as IMC-CS4) is tested in advanced solid tumors, including thyroid cancer |
TAM | NCT01525602 | Testing the effect of CSF-1R inhibitor (PLX3397) plus paclitaxel in patients with advanced solid tumors, including thyroid cancer |
Dendritic cells | NCT01856920 | Testing GI-6207, a vaccine made from baker’s yeast, targeting the CEA in patients with MTC |
Dendritic cells | NCT02239861 | Testing specific adoptive cytotoxic T cells targeting several tumor antigens (NY-ESO-1, MAGEA4, PRAME, survivin, and SSX) in patients with advanced solid tumors, including thyroid cancer patients |
T cells | NCT02054806 | Testing Pembrolizumab effect as monotherapy in advanced solid tumor patients, including a cohort of thyroid cancer patients |
TAM | NCT02452424 | Testing CSF-1R inhibitor (PLX3397) plus PD-1 inhibitor (Pembrolizumab) against advanced melanoma and other solid tumors, including thyroid |
TAM | NCT02718911 | Testing another CSF-1R inhibitor (LY3022855) plus Tremelimumab or Durvalumab (PD-1 inhibitors) in solid tumors |
| Â | NCT02614495 | Open label - two cohorts - phase I, II trial assessing the role of Sulfatinib in advanced MTC and RAI-R DTC |
T cells | NCT02501096 | Phase IB/II trial, currently recruiting patients with solid tumors to assess the maximum tolerated dose (MTD) for Lenvatinib in combination with Pembrolizumab during phase IB of the trial. A subsequent expansion phase II trial will evaluate the safety and efficacy of this combination |
T cells | NCT01988896 | Testing the effect of combining the PDL-1 inhibitor Atezolizumab, plus the mitogen-activated protein kinase (MAPK) inhibitor, Cobimetinib, in Locally Advanced or Metastatic Solid Tumors |
T cells | NCT01656642 | Phase IB trial investigating PD-L1 antibody Atezolizumab plus mutant BRAF inhibitor Vemurafenib for patients with BRAFV600 mutation-positive metastatic melanoma (even though this trial has no thyroid patients, its results will help in designing future thyroid trials using such a combination based on pharmacodynamics and kinetics of this study) |